42 related articles for article (PubMed ID: 38617449)
21. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.
Mohr R; Özdirik B; Lambrecht J; Demir M; Eschrich J; Geisler L; Hellberg T; Loosen SH; Luedde T; Tacke F; Hammerich L; Roderburg C
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540837
[TBL] [Abstract][Full Text] [Related]
22. A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer.
Liu Y; Tan M; Fang C; Chen X; Liu H; Feng Y; Zhang Y; Min W
Nanotechnology; 2021 Apr; 32(17):175101. PubMed ID: 33445163
[TBL] [Abstract][Full Text] [Related]
23. Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.
Azoulay D; Ramos E; Casellas-Robert M; Salloum C; Lladó L; Nadler R; Busquets J; Caula-Freixa C; Mils K; Lopez-Ben S; Figueras J; Lim C
JHEP Rep; 2021 Feb; 3(1):100190. PubMed ID: 33294830
[TBL] [Abstract][Full Text] [Related]
24. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies.
Freites-Martinez A; Santana N; Arias-Santiago S; Viera A
Actas Dermosifiliogr (Engl Ed); 2021 Jan; 112(1):90-92. PubMed ID: 32891586
[No Abstract] [Full Text] [Related]
25. The Importance of AFP in Liver Transplantation for HCC.
Özdemir F; Baskiran A
J Gastrointest Cancer; 2020 Dec; 51(4):1127-1132. PubMed ID: 32845425
[TBL] [Abstract][Full Text] [Related]
26. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study.
Hidaka H; Uojima H; Nakazawa T; Shao X; Hara Y; Iwasaki S; Wada N; Kubota K; Tanaka Y; Shibuya A; Kanoh Y; Kokubu S; Koizumi W
Hepatol Res; 2020 Sep; 50(9):1083-1090. PubMed ID: 32515895
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
28. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
[TBL] [Abstract][Full Text] [Related]
29. Challenges in liver cancer and possible treatment approaches.
Anwanwan D; Singh SK; Singh S; Saikam V; Singh R
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188314. PubMed ID: 31682895
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.
Cerrito L; Annicchiarico BE; Iezzi R; Gasbarrini A; Pompili M; Ponziani FR
World J Gastroenterol; 2019 Aug; 25(31):4360-4382. PubMed ID: 31496618
[TBL] [Abstract][Full Text] [Related]
31. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.
Moon AM; Singal AG; Tapper EB
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2650-2666. PubMed ID: 31401364
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
[TBL] [Abstract][Full Text] [Related]
33. Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version).
Chin J Cancer Res; 2019 Feb; 31(1):1-28. PubMed ID: 30996564
[No Abstract] [Full Text] [Related]
34. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
Ma R; Chen J; Liang Y; Lin S; Zhu L; Liang X; Cai X
Biomed Pharmacother; 2017 Apr; 88():459-468. PubMed ID: 28122312
[TBL] [Abstract][Full Text] [Related]
37. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Wahl RL; Jacene H; Kasamon Y; Lodge MA
J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract][Full Text] [Related]
39. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
40. A history of the treatment of primary liver cancer.
Bruix J
Clin Liver Dis (Hoboken); 2024; 23(1):e0147. PubMed ID: 38707239
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
